Conditions: Open-Angle Glaucoma Ocular Hypertension
Keywords: Glaucoma OAG OHT
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 202
Healthy volunteers: no

Brief summary:
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Detailed description:

Arms:
arm 1: Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks

Interventions: intervention 1: Travoprost 0.004%
Intervention descriptions: intervention 1: Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative

Protocol document: